drugset / Trial / NCT02717858

A Trial to Assess the Effects of Liraglutide on Gallbladder Emptying in Overweight and Obese Subjects.

NCT02717858 ↗

Phase 1 Completed 52 enrolled Novo Nordisk A/S
RandomizedParallel-groupDouble-blindTreatment

Summary

This trial is conducted in Europe. The aim of this trial is to investigate the effects of liraglutide on gallbladder emptying in overweight and obese subjects.

Timeline

Start
2016-03-16
Primary completion
2017-02-27
Completion
2017-02-27

Outcome

Missed primary endpoint

paper Mean 12-week GBEFmax (treatment difference -3.7%, 95% confidence interval [CI] -13.1, 5.7) and area under the GBEF curve in the first 60 minutes (-390% × min, 95% CI -919, 140) did not differ for liraglutide 3.0 mg (n = 23) vs placebo (n = 24). PMID 29892986 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Liraglutide Peptide 3 mg Subcutaneous